Pharmaceutical Logistics Data Programme
An institutional capability for turning fragmented operational information into a coherent, governed and reusable picture of pharmaceutical and related consumption across IFO.
IFO is the institutional structure bringing together two IRCCS institutes — the Istituto Nazionale Tumori Regina Elena and the Istituto Dermatologico San Gallicano — and is described in its own training materials as the only Italian hospital organisation including two IRCCS institutes. In a research hospital, logistics is simultaneously a clinical, organisational, economic and scientific problem: a unit of consumption can represent a patient treatment, a diagnostic procedure, a research protocol, a quality-control activity, a device-assisted service or a planned budget commitment. The programme responds to that fragmentation with a controlled analytical domain for actual consumption and related information, populated from governed AL Data Objects. The technical mapping covers 59 field-level rules, 10 logical source domains, 5 target Data Objects and 17 transformation categories.
- —Actual, budget and forecast scenarios
- —Calendar, organisation, hospital, department, drug, ATC and device dimensions
- —Total Cost = Quantity × Unit Cost, reconciled per scenario
- —Consumption interpreted by time, site, organisational unit, therapeutic and device identity
- —Indicators that can be explained, reconciled and traced rather than merely presented
- —Research-ready governed views prepared without bypassing institutional responsibilities
- fact_consumi
- fact_budget_consumi
- AL_laboratory_orders
- AL_laboratory_results
- AL_lab_panels
- AL_quality_control_data
- AL_lab_instruments_devices_EXT
Success is not the production of a technically correct dataset. Success is the routine use of a trusted institutional capability, in which pharmacists, controllers, clinical managers, researchers and academic partners work from the same definitions and understand how results were produced.
To explain the work at institutional and strategic level: why the programme matters to IFO, how it supports hospital pharmaceutical logistics, and why IFO's academic network makes the initiative particularly valuable. Solution design, code and physical schemas remain deliberately outside its scope.
Establish a shared and governed representation of pharmaceutical, device and related consumption across time, sites and organisational units.
Connect quantities and costs with budgets, forecasts and organisational accountability, enabling earlier and better-informed management action.
Improve the ability to investigate patterns, anomalies, unusual consumption and operational dependencies that may affect treatment continuity and safe care.
Ensure that figures can be traced to authoritative sources, interpreted consistently and regenerated under controlled rules.
Provide a higher-quality foundation for pharmacoeconomic analysis, observational studies, health-services research, technology assessment and student or specialist projects.
Build a model that can grow with IFO, accommodate new therapeutic areas and support future integration without losing semantic control.
- —An integrated view of consumption, cost and budget performance across IFO.
- —Improved visibility of structural trends and exceptional deviations.
- —A stronger basis for resource allocation, investment decisions and service planning.
- —Greater confidence that management indicators can be explained and reproduced.
- —Consistent visibility of products, therapeutic classes, quantities, units and costs.
- —Improved support for stock, consumption and expenditure analysis.
- —Better identification of unusual patterns, substitution effects and data-quality issues.
- —A basis for more structured dialogue with clinical departments and procurement.
- —Clearer linkage between consumption and organisational or clinical context.
- —Improved capacity to compare periods, sites and pathways without relying on local spreadsheets.
- —Support for multidisciplinary review of therapies, devices and associated operational impacts.
- —Greater transparency around the resource implications of complex care.
- —Coherent reconciliation of actuals, budgets and forecasts.
- —Improved analysis of price, quantity and mix effects.
- —More reliable preparation of procurement scenarios and contract discussions.
- —Faster investigation of discrepancies and clearer audit trails.
- —Reusable, documented and reproducible data assets for health-services and pharmacoeconomic studies.
- —Improved readiness for multicentre research and joint projects with universities.
- —Better support for cohort construction, protocol feasibility and operational research.
- —A stronger basis for demonstrating the real-world context in which therapies are delivered.
- —Access to a mature institutional case study in healthcare data governance.
- —Opportunities for theses, internships, specialist training and joint methodological work.
- —A practical environment in which clinical, economic and data-science perspectives can meet.
- —Exposure to the governance standards required in an IRCCS setting.
- 01Clinical meaning before technical convenience.
- 02Definitions that reflect pharmaceuticals, devices, organisational units, time periods and scenarios as they really are.
- 03Traceability of every published figure to authoritative sources.
- 04Data quality treated as part of the product, not as an afterthought.
- 05Versioned change: mappings, classifications and organisational structures documented so historical analyses remain intelligible.
- 06Academic usability without loss of control: research-ready governed views rather than bypassed responsibilities.
- 07Sustainable ownership across pharmacy, management, clinical governance, research and data architecture.
Deviations identified before period close rather than reconstructed afterwards.
Consistent indicators that can be explained, reconciled and traced rather than merely presented.
Comparable definitions and evidence prepared for regional, national or multicentre initiatives.
Governed views supporting pharmacoeconomics, health-technology assessment, pharmacoepidemiology and pharmacovigilance with university partners.
| Area | Indicator | Direction |
|---|---|---|
| Research | Feasibility studies, theses or joint analyses supported | Increase |
| Auditability | Share of indicators with documented provenance and rule version | Increase |
| Planning | Budget deviations identified before period close | Increase |
In a modern research hospital, excellence depends not only on possessing data, but on being able to explain what those data mean, where they came from, how they can be trusted and how they should be used.